Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 235.

https://doi.org/10.1182/blood-2019-123906

Published: 2019

Journal Articles

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Hanrry Jerry Paredes, MD MT(ASCP), M. Francisco Gonzalez, MD

Blood (2019) 134 (Supplement_1): 5189.

https://doi.org/10.1182/blood-2019-132019

Published: 2019

Journal Articles

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Blood (2018) 132 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2018-99-117293

Published: 2018

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD

Blood (2018) 132 (Supplement 1): 2969.

https://doi.org/10.1182/blood-2018-99-116678

Published: 2018

Journal Articles

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

Justin Kline, MD, Hongtao Liu, MD PhD, Tallarico Michael, MD, Andrew S Artz, MD, James Godfrey, MD, Emily K Curran, MD, Wendy Stock, MD, Sonali M. Smith, MD, Michael R. Bishop, MD

Blood (2018) 132 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2018-99-115108

Published: 2018

Journal Articles

A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients

Blood (2018) 132 (Supplement 1): 3118.

https://doi.org/10.1182/blood-2018-99-114899

Published: 2018

Journal Articles

Pembrolizumab (MK-3475) in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Stephen D. Smith, MD, Brian G. Till, MD, Sandra L. Kanan, ARNP, Andrew J. Cowan, MD, Qian Wu, PhD, Mazyar Shadman, MD, Katie Blue, Lauren Low, PA-C, Andrei R. Shustov, MD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 4125.

https://doi.org/10.1182/blood.V130.Suppl_1.4125.4125

Published: 2017

Journal Articles

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Antonio Rueda, Philippe Armand, MD PhD, Marek Trněný, MD PhD, Tatyana A Feldman, MD, Stephen M Ansell, MD PhD, Mariano Provencio, MD, Ulrich Jaeger, MD, Jonathon B Cohen, MDMS, Kerry J Savage, BSc, MD MSc, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo Domenech, MD

Blood (2017) 130 (Supplement 1): 651.

https://doi.org/10.1182/blood.V130.Suppl_1.651.651

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Propylthiouracil: A Well Known Cause of Agranulocytosis, but Can It Cause Aplastic Anemia?

Hira G. Shaikh, MD, Amir Kamran, MD, Prerna Mewawalla, MD

Blood (2017) 130 (Supplement 1): 4959.

https://doi.org/10.1182/blood.V130.Suppl_1.4959.4959

Published: 2017

Journal Articles

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Karen E Effinger, MD MS, John Bergsagel, MD, Taylor Lawrence, Frank G Keller, MD, Rebecca Williamson Lewis, MPH, Lillian Meacham, MD, Ann Mertens, PhD, Sharon M. Castellino, MD MSc

Blood (2017) 130 (Supplement 1): 3466.

https://doi.org/10.1182/blood.V130.Suppl_1.3466.3466

Published: 2017

Journal Articles

Superimposed Hypercoagulable and Hypocoagulable States: Elevated Von Willebrand Factor (vWF) Levels Secondary to Polycystic Ovary Syndrome Masking Von Willebrand Disease

Kristen M Scheitler, Post-Sophomore Fellow, Emily A Coberly, MD, A. Mosharraf Hossain, MD, Richard D Hammer, MD

Blood (2016) 128 (22): 4989.

https://doi.org/10.1182/blood.V128.22.4989.4989

Published: 2016

Journal Articles

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Richard T. Silver, Ariella Barel, Elena Lascu, BA,MA, Ellen K. Ritchie, MD, Gail J. Roboz, MD, Paul Christos, Attilio Orazi, MD, Duane C Hassane, PhD, Wayne Tam, MD PhD, Nicholas C.P. Cross, PhD

Blood (2016) 128 (22): 944.

https://doi.org/10.1182/blood.V128.22.944.944

Published: 2016

Journal Articles

Analysis of the Prevalence and Risk Factors of Adult Neutropenia in a Large Cohort in Japan

Yasuhisa Yokoyama, MD,PhD, Masahiko Gosho, PhD, Takahiro Suzuki, MD, PhD, Akiyoshi Takami, MD, PhD, Yasushi Miyazaki, MD PhD, Koichi Akashi, MD PhD, Shigeru Chiba, MD, PhD

Blood (2016) 128 (22): 4738.

https://doi.org/10.1182/blood.V128.22.4738.4738

Published: 2016

Journal Articles

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Nishitha M Reddy, M.B.B.S., David S Morgan, MD, John P Greer, Heidi Chen, Steven I. Park, MD, Kristy L. Richards, PhD MD

Blood (2015) 126 (23): 2739.

https://doi.org/10.1182/blood.V126.23.2739.2739

Published: 2015

Journal Articles

Bruton's Tyrosine Kinase Inhibition Is Associated with Manageable Cardiac Toxicity

Alison Romisher, Joseph Carver, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Rupal O'Quinn, MD, Bonnie Ky, MD, Anthony R. Mato, MD

Blood (2015) 126 (23): 4529.

https://doi.org/10.1182/blood.V126.23.4529.4529

Published: 2015

Journal Articles

Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors

Shah-Jalal Sarker, PhD FHEA, Gincy Elsa George, Kashfia Chowdhury, MSc, Gill Levitt, MD FRPCh, Judith Kingston, Andrew Lister, John G. Gribben, MD DSc, Ania Korszun, PhD MD FRCPsych

Blood (2014) 124 (21): 1309.

https://doi.org/10.1182/blood.V124.21.1309.1309

Published: 2014

Journal Articles

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

Richard T. Silver, Elena Lascu, Eric J. Feldman, MD, Ellen Ritchie, MD, Gail J. Roboz, MD, Maria Teresa De Sancho, MD, MSc, Ruth Bauman, Attilio Orazi, MD

Blood (2013) 122 (21): 4053.

https://doi.org/10.1182/blood.V122.21.4053.4053

Published: 2013

Journal Articles

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Deniz Peker, MD, Eric Padron, MD, Pedro Horna, MD, John M. Bennett, MD, Xiaohui Zhang, MD, P.K. Epling-Burnette, PharmD, PhD, Jeffrey E Lancet, MD, Javier Pinilla, Lynn Moscinski, MD, Alan F. List, MD, Rami S. Komrokji, MD, Ling Zhang, MD

Blood (2012) 120 (21): 1712.

https://doi.org/10.1182/blood.V120.21.1712.1712

Published: 2012

NARROW

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Complete Hematologic and Cytogenetic Remission of Acute Myeloid Leukemia in an Elderly Patient Treated with Decitabine and Venetoclax: A Case Report

Endocrinopathies Following Allogeneic Stem Cell Transplantation: 10 Years Follow-up in 402 Patients

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Pembrolizumab for the Treatment of Disease Relapse Following Allogeneic Hematopoietic Cell Transplantation

A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients

Pembrolizumab (MK-3475) in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Propylthiouracil: A Well Known Cause of Agranulocytosis, but Can It Cause Aplastic Anemia?

Outcomes within Five Years from Diagnosis in Pediatric Hodgkin Lymphoma Patients Following Contemporary Therapy

Superimposed Hypercoagulable and Hypocoagulable States: Elevated Von Willebrand Factor (vWF) Levels Secondary to Polycystic Ovary Syndrome Masking Von Willebrand Disease

The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFNα) Treatment in Early Myelofibrosis

Analysis of the Prevalence and Risk Factors of Adult Neutropenia in a Large Cohort in Japan

Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab Following Standard Chemotherapy for Patients with Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL) - Final Results

Bruton's Tyrosine Kinase Inhibition Is Associated with Manageable Cardiac Toxicity

Late Effects: An Evaluation of Contrasting Physical and Psychological Experiences Between Child and Adult Hodgkin Survivors

Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis

A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only